Tumor suppressor gene inactivation in myeloid malignancies

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 4, 2008, Pages 601-614

  Wong, Jasmine C ^a   Le Beau, Michelle M ^b   Shannon, Kevin ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

myeloid malignancies; tumor suppressor genes

Indexed keywords

NEUROFIBROMIN; PROTEIN P53; PROTEIN RPS14; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

5Q- SYNDROME; BONE MARROW CANCER; CARCINOGENESIS; CHROMOSOME 20; CHROMOSOME 20Q; CHROMOSOME 5; CHROMOSOME 5Q; CHROMOSOME 7; CHROMOSOME 7Q; CHROMOSOME 9; CHROMOSOME 9Q; CHROMOSOME BAND; CHROMOSOME DELETION; GENE INACTIVATION; GENE REARRANGEMENT; HAPLOTYPE; HUMAN; LEUKEMOGENESIS; MOLECULAR CLONING; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ANIMALS; CHROMOSOME DELETION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; MYELOPROLIFERATIVE DISORDERS;

EID: 56549107802     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.09.001     Document Type: Review

References (107)

1. Mullighan C.G., Goorha S., Radtke I., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 (2007) 758-764
2. Rowley J.D. The role of chromosome translocations in leukemogenesis. Seminars in Hematology 36 (1999) 59-72
3. Look A. Oncogenic transcription factors in the human acute leukemias. Science 278 (1997) 1059-1064
4. Shannon K.M. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Current Opinion in Hematology 3 (1995) 305-308
5. Kelly L., Clark J., and Gilliland D.G. Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications. Current Opinion in Oncology 14 (2002) 10-18
6. Gilliland D.G., and Tallman M.S. Focus on acute leukemias. Cancer Cell 1 (2002) 417-420
7. Van Etten R.A., and Shannon K.M. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell 6 (2004) 547-552
8. Kralovics R., Guan Y., and Prchal J.T. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology 30 (2002) 229-236
9. Fitzgibbon J., Smith L.L., Raghavan M., et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Research 65 (2005) 9152-9154
10. Cook W.D., and McCaw B.J. Accommodating haploinsufficient tumor suppressor genes in Knudson's model. Oncogene 19 (2000) 3434-3438
11. Quon K.C., and Berns A. Haplo-insufficiency? Let me count the ways. Genes & Development 15 (2001) 2917-2921
12. Vives V., Su J., Zhong S., et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes & Development 20 (2006) 1262-1267
13. Joslin J.M., Fernald A.A., Tennant T.R., et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 110 (2007) 719-726
14. Cichowski K., and Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104 (2001) 593-604
15. Side L., Emanuel P., Taylor B., et al. Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1. Blood 92 (1998) 267-273
16. Bader J.L., and Miller R.W. Neurofibromatosis and childhood leukemia. The Journal of Pediatrics 92 (1978) 925-929
17. Stiller C.A., Chessells J.M., and Fitchett M. Neurofibromatosis and childhood leukemia/lymphoma: A population-based UKCCSG study. British Journal of Cancer 70 (1994) 969-972
18. Emanuel P.D., Shannon K.M., and Castleberry R.P. Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. Molecular Medicine Today 2 (1996) 468475
19. Arico M., Biondi A., and Pui C.-H. Juvenile myelomonocytic leukemia. Blood 90 (1997) 479-488
20. Emanuel P.D., Bates L.J., Castleberry R.P., et al. Seletive hypersensitivity to granulocyte-macrophage colony stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77 (1991) 925-929
21. Shannon K.M., O'Connell P., Martin G.A., et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. The New England Journal of Medicine 330 (1994) 597-601
22. Side L., Taylor B., Cayouette M., et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. The New England Journal of Medicine 336 (1997) 1713-1720
23. Stephens K., Weaver M., Leppig K.A., et al. Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. Blood 108 (2006) 1684-1689
24. Bollag G., Clapp D.W., Shih S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in murine and human hematopoietic cells. Nature Genetics 12 (1996) 144-148
25. Birnbaum R.A., O'Marcaigh A., Wardak Z., et al. Nf1 and Gmcsf interact in myeloid leukemogenesis. Molecular Cell 5 (2000) 189-195
26. Chao R.C., Pyzel U., Fridlyand J., et al. Therapy-induced malignant neoplasms in Nf1 mutant mice. Cancer Cell 8 (2005) 337-348
27. Mahgoub N., Taylor B., Le Beau M., et al. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 93 (1999) 3617-3623
28. Mahgoub N., Taylor B.R., Gratiot M., et al. In vitro and In vivo effects of a farnesyltransferase inhibitor on Nf1- deficient hematopoietic cells. Blood 94 (1999) 2469-2476
29. Balgobind B.V., Van Vlierberghe P., van den Ouweland A.M., et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood 111 (2008) 4322-4328
30. Ingram D.A., Yang F.C., Travers J.B., et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. The Journal of Experimental Medicine 191 (2000) 181-188
31. Riley T., Sontag E., Chen P., et al. Transcriptional control of human p53-regulated genes. Nature Reviews. Molecular Cell Biology 9 (2008) 402-412
32. Fenaux P., Jonveaux P., Quiquandon I., et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78 (1991) 1652-1657
33. Kurosawa M., Okabe M., Kunieda Y., et al. Analysis of the p53 gene mutations in acute myelogenous leukemia: the p53 gene mutations associated with a deletion of chromosome 17. Annals of Hematology 71 (1995) 83-87
34. Nahi H., Lehmann S., Bengtzen S., et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leukemia & Lymphoma 49 (2008) 508-516
35. Stirewalt D.L., Kopecky K.J., Meshinchi S., et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97 (2001) 3589-3595
36. Horiike S., Misawa S., Kaneko H., et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype. Leukemia 13 (1999) 1235-1242
37. Side L.E., Curtiss N.P., Teel K., et al. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes, Chromosomes & Cancer 39 (2004) 217-223
38. Lothe R.A., Smith-Sorensen B., Hektoen M., et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes, Chromosomes & Cancer 30 (2001) 202-206
39. Christiansen D.H., Andersen M.K., and Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy- related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology 19 (2001) 1405-1413
40. Skorski T., Nieborowska-Skorska M., Wlodarski P., et al. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proceedings of the National Academy of Sciences of the United States of America 93 (1996) 13137-13142
41. Wendel H.G., de Stanchina E., Cepero E., et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 7444-7449
42. Higuchi M., O'Brien D., Kumaravelu P., et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1 (2002) 63-74
43. Slovak M.L., Bedell V., Popplewell L., et al. 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes, Chromosomes & Cancer 33 (2002) 379-394
44. Loh M.L., Goldwasser M.A., Silverman L.B., et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107 (2006) 4508-4513
45. Rubnitz J.E., Wichlan D., Devidas M., et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Journal of Clinical Oncology 26 (2008) 2186-2191
46. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. [see comments]. Nature Genetics 23 (1999) 166-175
47. Osato M., Asou N., Abdalla E., et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93 (1999) 1817-1824
48. Preudhomme C., Warot-Loze D., Roumier C., et al. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood 96 (2000) 2862-2869
49. Harada H., Harada Y., Niimi H., et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103 (2004) 2316-2324
50. Christiansen D.H., Andersen M.K., and Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 104 (2004) 1474-1481
51. Okuno Y., Huang G., Rosenbauer F., et al. Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Molecular and Cellular Biology 25 (2005) 2832-2845
52. DeKoter R.P., Kamath M.B., and Houston I.B. Analysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models. Blood Cells, Molecules & Diseases 39 (2007) 316-320
53. Kastner P., and Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. The International Journal of Biochemistry & Cell Biology 40 (2008) 22-27
54. Scott E.W., Simon M.C., Anastasi J., et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 265 (1994) 1573-1577
55. McKercher S.R., Torbett B.E., Anderson K.L., et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. The EMBO Journal 15 (1996) 5647-5658
56. Walter M.J., Park J.S., Ries R.E., et al. Reduced PU.1 expression causes myeloid progenitor expansion and increased leukemia penetrance in mice expressing PML-RARalpha. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 12513-12518
57. Rosenbauer F., Wagner K., Kutok J.L., et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nature Genetics 36 (2004) 624-630
58. Cook W.D., McCaw B.J., Herring C., et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood 104 (2004) 3437-3444
59. Metcalf D., Dakic A., Mifsud S., et al. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 1486-1491
60. Mueller B.U., Pabst T., Osato M., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 100 (2002) 998-1007
61. Mueller B.U., Pabst T., Osato M., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 101 (2003) 2074
62. Dohner K., Tobis K., Bischof T., et al. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM). Blood 102 (2003) 3850 author reply 3850-3851
63. Lamandin C., Sagot C., Roumier C., et al. Are PU.1 mutations frequent genetic events in acute myeloid leukemia (AML)?. Blood 100 (2002) 4680-4681
64. Vegesna V., Takeuchi S., Hofmann W.K., et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leukemia Research 26 (2002) 451-457
65. Steidl U., Rosenbauer F., Verhaak R.G., et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nature Genetics 38 (2006) 1269-1277
66. Vangala R.K., Heiss-Neumann M.S., Rangatia J.S., et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood 101 (2003) 270-277
67. Mueller B.U., Pabst T., Fos J., et al. ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. Blood 107 (2006) 3330-3338
68. Zheng R., Friedman A.D., Levis M., et al. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression. Blood 103 (2004) 1883-1890
69. Boultwood J., Fidler C., Strickson A.J., et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 99 (2002) 4638-4641
70. Ebert B.L., Pretz J., Bosco J., et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451 (2008) 335-339
71. Ebert B.L., Lee M.M., Pretz J.L., et al. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood 105 (2005) 4620-4626
72. Luna-Fineman S., Shannon K., and Lange B.J. Childhood monosomy 7: epidemiology, biology and mechanistic implications. Blood 85 (1995) 1985-1999
73. Le Beau M.M., Espinosa III R., Davis E.M., et al. Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood 88 (1996) 1930-1935
74. Kratz C.P., Emerling B.M., Donovan S., et al. Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. Genomics 77 (2001) 171-180
75. Emerling B.M., Bonifas J., Kratz C.P., et al. MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene 21 (2002) 4849-4854
76. Curtiss N.P., Bonifas J.M., Lauchle J.O., et al. Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. Genomics 85 (2005) 600-607
77. Kere J., Ruutu T., Lahtinen R., et al. Molecular characterization of chromosome 7 long arm deletions in myeloid disorders. Blood 70 (1987) 1349-1353
78. Kere J., Donis-Keller H., Ruutu T., et al. Chromosome 7 long-arm deletions in myeloid disorders: terminal DNA sequences are commonly conserved and breakpoints vary. Cytogenetics and Cell Genetics 50 (1989) 226-229
79. Fischer K., Frohling S., Scherer S., et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. Blood 89 (1997) 2035-2041
80. Liang H., Fairman J., Claxton D.F., et al. Molecular anatomy of chromosome 7q deletions in myeloid leukemia: Evidence for multiple critical loci. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 3781-3785
81. Tosi S., Scherer S.W., Giudici G., et al. Delineation of multiple deleted regions in 7q in myeloid disorders. Genes, Chromosomes & Cancer 25 (1999) 384-392
82. Zhao N., Stoffel A., Wang P.W., et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 6948-6953
83. Lai F., Godley L.A., Joslin J., et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 71 (2001) 235-245
84. Liu T.X., Becker M.W., Jelinek J., et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nature Medicine 13 (2007) 78-83
85. Wattel E., Lai J.L., Hebbar M., et al. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?. Leukemia Research 17 (1993) 921-926
86. Davis M.P., Dewald G.W., Pierre R.V., et al. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genetics and Cytogenetics 12 (1984) 63-71
87. Aatola M., Armstrong E., Teerenhovi L., et al. Clinical significance of the del(20q) chromosome in hematologic disorders. Cancer Genetics and Cytogenetics 62 (1992) 75-80
88. Fenaux P., Morel P., and Lai J.L. Cytogenetics of myelodysplastic syndromes. Seminars in Hematology 33 (1996) 127-138
89. Heim S., and Mitelman F. Cytogenetic analysis in the diagnosis of acute leukemia. Cancer 70 (1992) 1701-1709
90. Kurtin P.J., Dewald G.W., Shields D.J., et al. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. American Journal of Clinical Pathology 106 (1996) 680-688
91. Nacheva E., Holloway T., Carter N., et al. Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes. Cancer Genetics and Cytogenetics 80 (1995) 87-94
92. Roulston D., Espinosa III R., Stoffel M., et al. Molecular genetics of myeloid leukemia: identification of the commonly deleted segment of chromosome 20. Blood 82 (1993) 3424-3429
93. Asimakopoulos F.A., White N.J., Nacheva E., et al. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood 84 (1994) 3086-3094
94. Bench A.J., Aldred M.A., Humphray S.J., et al. A detailed physical and transcriptional map of the region of chromosome 20 that is deleted in myeloproliferative disorders and refinement of the common deleted region. Genomics 49 (1998) 351-362
95. Bench A.J., Nacheva E.P., Hood T.L., et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes. UK Cancer Cytogenetics Group (UKCCG). Oncogene 19 (2000) 3902-3913
96. Wang P.W., Eisenbart J.D., Espinosa III R., et al. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. Genomics 67 (2000) 28-39
97. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92 (1998) 2322-2333
98. Peniket A., Wainscoat J., Side L., et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. British Journal of Haematology 129 (2005) 210-220
99. Schoch C., Haase D., Haferlach T., et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 10 (1996) 1288-1295
100. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1312-1320
101. Raimondi S.C., Chang M.N., Ravindranath Y., et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 94 (1999) 3707-3716
102. Sweetser D.A., Peniket A.J., Haaland C., et al. Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia. Genes, Chromosomes & Cancer 44 (2005) 279-291
103. Dayyani F., Wang J., Yeh J.R., et al. Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival. Blood 111 (2008) 4338-4347
104. Ramirez-Solis R., Liu P., and Bradley A. Chromosome engineering in mice. Nature 378 (1995) 720-724
105. van der Weyden L., and Bradley A. Mouse chromosome engineering for modeling human disease. Annual Review of Genomics and Human Genetics 7 (2006) 247-276
106. Shannon K.M., Le Beau M.M., Largaespada D.A., et al. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Seminars in Cancer Biology 11 (2001) 191-200
107. Bagchi A., Papazoglu C., Wu Y., et al. CHD5 is a tumor suppressor at human 1p36. Cell 128 (2007) 459-475